CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: PEGylated liposomes</title> <meta name="description" content="Search results for: PEGylated liposomes"> <meta name="keywords" content="PEGylated liposomes"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="PEGylated liposomes" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="PEGylated liposomes"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 72</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: PEGylated liposomes</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">72</span> Resveratrol Incorporated Liposomes Prepared from Pegylated Phospholipids and Cholesterol</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mont%20Kumpugdee-Vollrath">Mont Kumpugdee-Vollrath</a>, <a href="https://publications.waset.org/abstracts/search?q=Khaled%20Abdallah"> Khaled Abdallah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Liposomes and pegylated liposomes were widely used as drug delivery system in pharmaceutical field since a long time. However, in the former time, polyethylene glycol (PEG) was connected into phospholipid after the liposomes were already prepared. In this paper, we intend to study the possibility of applying phospholipids which already connected with PEG and then they were used to prepare liposomes. The model drug resveratrol was used because it can be applied against different diseases. Cholesterol was applied to stabilize the membrane of liposomes. The thin film technique in a laboratory scale was a preparation method. The liposomes were then characterized by nanoparticle tracking analysis (NTA), photon correlation spectroscopy (PCS) and light microscopic techniques. The stable liposomes can be produced and the particle sizes after filtration were in nanometers. The 2- and 3-chains-PEG-phospholipid (PL) caused in smaller particle size than the 4-chains-PEG-PL. Liposomes from PL 90G and cholesterol were stable during storage at 8 °C of 56 days because the particle sizes measured by PCS were almost not changed. There was almost no leakage of resveratrol from liposomes PL 90G with cholesterol after diffusion test in dialysis tube for 28 days. All liposomes showed the sustained release during measuring time of 270 min. The maximum release amount of 16-20% was detected with liposomes from 2- and 3-chains-PEG-PL. The other liposomes gave max. release amount of resveratrol only of 10%. The release kinetic can be explained by Korsmeyer-Peppas equation.  <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=liposome" title="liposome">liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=NTA" title=" NTA"> NTA</a>, <a href="https://publications.waset.org/abstracts/search?q=resveratrol" title=" resveratrol"> resveratrol</a>, <a href="https://publications.waset.org/abstracts/search?q=pegylation" title=" pegylation"> pegylation</a>, <a href="https://publications.waset.org/abstracts/search?q=cholesterol" title=" cholesterol"> cholesterol</a> </p> <a href="https://publications.waset.org/abstracts/53135/resveratrol-incorporated-liposomes-prepared-from-pegylated-phospholipids-and-cholesterol" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/53135.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">185</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">71</span> Ultrasound Enhanced Release of Active Targeting Liposomes Used for Cancer Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Najla%20M.%20Salkho">Najla M. Salkho</a>, <a href="https://publications.waset.org/abstracts/search?q=Vinod%20Paul"> Vinod Paul</a>, <a href="https://publications.waset.org/abstracts/search?q=Pierre%20Kawak"> Pierre Kawak</a>, <a href="https://publications.waset.org/abstracts/search?q=Rute%20F.%20Vitor"> Rute F. Vitor</a>, <a href="https://publications.waset.org/abstracts/search?q=Ana%20M.%20Martin"> Ana M. Martin</a>, <a href="https://publications.waset.org/abstracts/search?q=Nahid%20Awad"> Nahid Awad</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Al%20Sayah"> Mohammad Al Sayah</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghaleb%20A.%20Husseini"> Ghaleb A. Husseini</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Liposomes are popular lipid bilayer nanoparticles that are highly efficient in encapsulating both hydrophilic and hydrophobic therapeutic drugs. Liposomes promote a low risk controlled release of the drug avoiding the side effects of the conventional chemotherapy. One of the great potentials of liposomes is the ability to attach a wide range of ligands to their surface producing ligand-mediated active targeting of cancer tumour with limited adverse off-target effects. Ultrasound can also aid in the controlled and specified release of the drug from the liposomes by breaking it apart and releasing the drug in the specific location where the ultrasound is applied. Our research focuses on the synthesis of PEGylated liposomes (contain poly-ethylene glycol) encapsulated with the model drug calcein and studying the effect of low frequency ultrasound applied at different power densities on calcein release. In addition, moieties are attached to the surface of the liposomes for specific targeting of the cancerous cells which over-express the receptors of these moieties, ultrasound is then applied and the release results are compared with the moiety free liposomes. The results showed that attaching these moieties to the surface of the PEGylated liposomes not only enhance their active targeting but also stimulate calcein release from these liposomes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=active%20targeting" title="active targeting">active targeting</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=moieties" title=" moieties"> moieties</a>, <a href="https://publications.waset.org/abstracts/search?q=ultrasound" title=" ultrasound"> ultrasound</a> </p> <a href="https://publications.waset.org/abstracts/78619/ultrasound-enhanced-release-of-active-targeting-liposomes-used-for-cancer-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/78619.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">602</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">70</span> Pegylated Liposomes of Trans Resveratrol, an Anticancer Agent, for Enhancing Therapeutic Efficacy and Long Circulation</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20R.%20Vijayakumar">M. R. Vijayakumar</a>, <a href="https://publications.waset.org/abstracts/search?q=Sanjay%20Kumar%20Singh"> Sanjay Kumar Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Lakshmi"> Lakshmi</a>, <a href="https://publications.waset.org/abstracts/search?q=Hithesh%20Dewangan"> Hithesh Dewangan</a>, <a href="https://publications.waset.org/abstracts/search?q=Sanjay%20Singh"> Sanjay Singh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Trans resveratrol (RES) is a natural molecule proved for cancer preventive and therapeutic activities devoid of any potential side effects. However, the therapeutic application of RES in disease management is limited because of its rapid elimination from blood circulation thereby low biological half life in mammals. Therefore, the main objective of this study is to enhance the circulation as well as therapeutic efficacy using PEGylated liposomes. D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) is applied as steric surface decorating agent to prepare RES liposomes by thin film hydration method. The prepared nanoparticles were evaluated by various state of the art techniques such as dynamic light scattering (DLS) technique for particle size and zeta potential, TEM for shape, differential scanning calorimetry (DSC) for interaction analysis and XRD for crystalline changes of drug. Encapsulation efficiency and invitro drug release were determined by dialysis bag method. Cancer cell viability studies were performed by MTT assay, respectively. Pharmacokinetic studies were performed in sprague dawley rats. The prepared liposomes were found to be spherical in shape. Particle size and zeta potential of prepared formulations varied from 64.5±3.16 to 262.3±7.45 nm and -2.1 to 1.76 mV, respectively. DSC study revealed absence of potential interaction. XRD study revealed presence of amorphous form in liposomes. Entrapment efficiency was found to be 87.45±2.14 % and the drug release was found to be controlled up to 24 hours. Minimized MEC in MTT assay and tremendous enhancement in circulation time of RES PEGylated liposomes than its pristine form revealed that the stearic stabilized PEGylated liposomes can be an alternative tool to commercialize this molecule for chemopreventive and therapeutic applications in cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=trans%20resveratrol" title="trans resveratrol">trans resveratrol</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20nanotechnology" title=" cancer nanotechnology"> cancer nanotechnology</a>, <a href="https://publications.waset.org/abstracts/search?q=long%20circulating%20liposomes" title=" long circulating liposomes"> long circulating liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=bioavailability%20enhancement" title=" bioavailability enhancement"> bioavailability enhancement</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes%20for%20cancer%20therapy" title=" liposomes for cancer therapy"> liposomes for cancer therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=PEGylated%20liposomes" title=" PEGylated liposomes"> PEGylated liposomes</a> </p> <a href="https://publications.waset.org/abstracts/17397/pegylated-liposomes-of-trans-resveratrol-an-anticancer-agent-for-enhancing-therapeutic-efficacy-and-long-circulation" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17397.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">589</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">69</span> Release of Calcein from Liposomes Using Low and High Frequency Ultrasound</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ghaleb%20A.%20Husseini">Ghaleb A. Husseini</a>, <a href="https://publications.waset.org/abstracts/search?q=Salma%20E.%20Ahmed"> Salma E. Ahmed</a>, <a href="https://publications.waset.org/abstracts/search?q=Hesham%20G.%20Moussa"> Hesham G. Moussa</a>, <a href="https://publications.waset.org/abstracts/search?q=Ana%20M.%20Martins"> Ana M. Martins</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Al-Sayah"> Mohammad Al-Sayah</a>, <a href="https://publications.waset.org/abstracts/search?q=Nasser%20Qaddoumi"> Nasser Qaddoumi </a> </p> <p class="card-text"><strong>Abstract:</strong></p> This abstract aims to investigate the use of targeted liposomes as anticancer drug carriers in vitro in combination with ultrasound applied as drug trigger; in order to reduce the side effects caused by traditional chemotherapy. Pegylated liposomes were used to encapsulate calcein and then release this model drug when 20-kHz, 40-kHz, 1-MHz and 3-MHz ultrasound were applied at different acoustic power densities. Fluorescence techniques were then used to measure the percent drug release of calcein from these targeted liposomes. Results showed that as the power density increases, at the four frequencies studied, the release of calcein also increased. Based on these results, we believe that ultrasound can be used to increase the rate and amount of chemotherapeutics release from liposomes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=liposomes" title="liposomes">liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=calcein%20release" title=" calcein release"> calcein release</a>, <a href="https://publications.waset.org/abstracts/search?q=high%20frequency%20ultrasound" title=" high frequency ultrasound"> high frequency ultrasound</a>, <a href="https://publications.waset.org/abstracts/search?q=low%20frequency%20ultrasound" title=" low frequency ultrasound"> low frequency ultrasound</a>, <a href="https://publications.waset.org/abstracts/search?q=fluorescence%20techniques" title=" fluorescence techniques"> fluorescence techniques</a> </p> <a href="https://publications.waset.org/abstracts/24679/release-of-calcein-from-liposomes-using-low-and-high-frequency-ultrasound" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24679.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">424</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">68</span> Novel Liposomal Nanocarriers For Long-term Tumor Imaging</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20Ahrari">Mohamad Ahrari</a>, <a href="https://publications.waset.org/abstracts/search?q=Kayvan%20Sadri"> Kayvan Sadri</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahmoud%20Reza%20Jafari"> Mahmoud Reza Jafari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> PEGylated liposomes have a smaller volume of distribution and decreased clearance, consequently, due to their more prolonged presence in bloodstream and maintaining their stability during this period, these liposomes can be applied for imaging tumoral sites. The purpose of this study is to develop an appropriate radiopharmaceutical agent in long-term imaging for improved diagnosis and evaluation of tumors. In this study, liposomal formulations encapsulating albumin is synthesized by solvent evaporation method along with homogenization, and their characteristics were assessed. Then these liposomes labeled by Philips method and the rate of stability of labeled liposomes in serum, and ultimately the rate of biodistribution and gamma scintigraphy in C26-colon carcinoma tumor-bearing mice, were studied. The result of the study of liposomal characteristics displayed that capable of accumulating in tumor sites based of EPR phenomenon. these liposomes also have high stability for maintaining encapsulated albumin in a long time. In the study of biodistribution of these liposomes in mice, they accumulated more in the kidney, liver, spleen, and tumor sites, which, even after clearing formulations in the bloodstream, they existed in high levels in these organs up to 96 hours. In gamma scintigraphy also, organs with high activity accumulation from early hours up to 96 hours were visible in the form of hot spots. concluded that PEGylated liposomal formulation encapsulating albumin can be labeled with In-Oxine, and obtained stabilized formulation for long-term imaging, that have more favorable conditions for the evaluation of tumors and it will cause early diagnosis of tumors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nano%20liposome" title="nano liposome">nano liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=111In-oxine" title=" 111In-oxine"> 111In-oxine</a>, <a href="https://publications.waset.org/abstracts/search?q=imaging" title=" imaging"> imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title=" biodistribution"> biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor" title=" tumor"> tumor</a> </p> <a href="https://publications.waset.org/abstracts/162894/novel-liposomal-nanocarriers-for-long-term-tumor-imaging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/162894.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">113</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">67</span> Development and Characterization of Double Liposomes Based Dual Drug Delivery System for H. Pylori Targeting</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ashish%20Kumar%20Jain">Ashish Kumar Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=Deepak%20Mishra"> Deepak Mishra</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The objective of the present investigation was to prepare and evaluate a vesicular dual drug delivery system for effective management of mucosal ulcer. Inner encapsulating and Double liposomes were prepared by glass bead and reverse phase evaporation method respectively. The formulation consisted of inner liposomes bearing Ranitidine Bismuth Citrate (RBC) and outer liposomes encapsulating Amoxicillin trihydrate (AMOX). The optimized inner liposomes and double liposomes were extensively characterized for vesicle size, morphology, zeta potential, vesicles count, entrapment efficiency and in vitro drug release. In vitro, the double liposomes demonstrated a sustained release of AMOX and RBC viz 91.4±1.8% and 77.2±2.1% respectively at the end of 72 hr. Furthermore binding specificity and targeting propensity toward H. pylori (SKP-56) was confirmed by agglutination and in situ adherence assay. Reduction of the absolute alcohol induced ulcerogenic index from 3.01 ± 0.25 to 0.31 ± 0.09 and 100% H. pylori clearance rate was observed. These results suggested that double liposomes are potential vector for the development of dual drug delivery for effective treatment of H. pylori-associated peptic ulcer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=double%20liposomes" title="double liposomes">double liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20pylori%20targeting" title=" H. pylori targeting"> H. pylori targeting</a>, <a href="https://publications.waset.org/abstracts/search?q=PE%20liposomes" title=" PE liposomes"> PE liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=glass-beads%20method" title=" glass-beads method"> glass-beads method</a>, <a href="https://publications.waset.org/abstracts/search?q=peptic%20ulcers" title=" peptic ulcers"> peptic ulcers</a> </p> <a href="https://publications.waset.org/abstracts/18114/development-and-characterization-of-double-liposomes-based-dual-drug-delivery-system-for-h-pylori-targeting" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18114.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">449</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">66</span> Pegylated Interferon in HCV Genotype 3 Relapser to Conventional Interferon in Pakistani Population</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Saad%20Khalid%20Niaz">Saad Khalid Niaz</a>, <a href="https://publications.waset.org/abstracts/search?q=Arif%20Mahmood%20Siddiqui"> Arif Mahmood Siddiqui</a>, <a href="https://publications.waset.org/abstracts/search?q=Afzal%20Haqi"> Afzal Haqi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Estimated prevalence of Hepatitis C in Pakistan is 5% of which 78 % are Genotype 3, in which Response to conventional interferon is reported to be 70%. Objective: To determine the efficacy of pegylated interferon 20 kDa (Unipeg) plus ribavirin (Ribazole) in HCV genotype 3 patients who relapsed to conventional interferon. Methods: This is an ongoing study of 20 enrolled patients. Pegylated interferon alfa-2a 20 kDa 180 mcg weekly with ribavirin, were administered for a period of 24 weeks. Virological Responses were measured by Qualitative HCV RNA at weeks 4, 12, 24 and 48 to determine Rapid Virological Response (RVR), Early Virological Response (EVR), End of Treatment (ETR) and Sustained Virological Response (SVR), respectively. EVR was done for those who didn’t achieve RVR. Results: Males were 12 (60%) and mean age was 38.5 ±7.62 years. Out of 20 recruited patients, all completed 4 weeks therapy; RVR was achieved in 8 (40%) patients. One patient was lost to follow up and one yet to visit at 12 weeks. From 10 patients, 8 (80%) patients achieved EVR. Out of intent-to-treat patients, 15 completed 24 weeks therapy, ETR was achieved in 14 (93%) patients and 9 patients completed post therapy follow-up, of which, 8 (89%) patients achieved SVR. Conclusion: Our interim data demonstrates that Pegylated Interferon alfa-2a 20 kDa 180 mcg (Unipeg) in combination with Ribavirin (Ribazole) has shown promising results in treating HCV Genotype 3 patients who relapsed to conventional interferon. We recommend use of Pegylated Interferon in Relapsers with Genotype 3 when financial constraints limit the use of oral antivirals. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=pegylated%20interferon%20%28unipeg%29" title="pegylated interferon (unipeg)">pegylated interferon (unipeg)</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20c" title=" hepatitis c"> hepatitis c</a>, <a href="https://publications.waset.org/abstracts/search?q=relapsers" title=" relapsers"> relapsers</a>, <a href="https://publications.waset.org/abstracts/search?q=Pakistan" title=" Pakistan"> Pakistan</a> </p> <a href="https://publications.waset.org/abstracts/42845/pegylated-interferon-in-hcv-genotype-3-relapser-to-conventional-interferon-in-pakistani-population" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42845.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">309</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">65</span> Optimizing the Nanoliposome of Nisin Produced by Sonication</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Seyed%20Moslemi%20S.%20A.">Seyed Moslemi S. A. </a>, <a href="https://publications.waset.org/abstracts/search?q=Hesari%20J."> Hesari J.</a>, <a href="https://publications.waset.org/abstracts/search?q=Valizadeh%20H."> Valizadeh H.</a>, <a href="https://publications.waset.org/abstracts/search?q=Rezaiee-Mokaram%20R."> Rezaiee-Mokaram R.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nanotechnology and nanoscience and related fields in this area, will impact on daily human life in the not too distant future. The basic materials of liposomes are lipids. Lipids that can be used to build liposomes can be provided from variety of sources. In this research, lecithin and cholesterol were used to prepare liposomes. Probe sonicator was used to minimize the particles of liposome and make nanoliposomes. Encapsulation efficiency were analyzed with pyrogallol red indicator and autoanalizer equipment. The smallest particle size was 220 nanometer( 100 mg lecithin, 50 mg cholestrol, 12 min and amplitude of 90%). The highest encapsulation efficiency was 13.5%( 120 mg lecithin,45 mg cholestrol, 12 min and ampilitude of 92%). <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=optimizing" title="optimizing">optimizing</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoliposome" title=" nanoliposome"> nanoliposome</a>, <a href="https://publications.waset.org/abstracts/search?q=nisin" title=" nisin"> nisin</a>, <a href="https://publications.waset.org/abstracts/search?q=cheese" title=" cheese"> cheese</a> </p> <a href="https://publications.waset.org/abstracts/31462/optimizing-the-nanoliposome-of-nisin-produced-by-sonication" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/31462.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">483</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">64</span> Poly-ε-Caprolactone Nanofibers with Synthetic Growth Factor Enriched Liposomes as Controlled Drug Delivery System</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vera%20Sovkova">Vera Sovkova</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrea%20Mickova"> Andrea Mickova</a>, <a href="https://publications.waset.org/abstracts/search?q=Matej%20Buzgo"> Matej Buzgo</a>, <a href="https://publications.waset.org/abstracts/search?q=Karolina%20Vocetkova"> Karolina Vocetkova</a>, <a href="https://publications.waset.org/abstracts/search?q=Eva%20Filova"> Eva Filova</a>, <a href="https://publications.waset.org/abstracts/search?q=Evzen%20Amler"> Evzen Amler</a> </p> <p class="card-text"><strong>Abstract:</strong></p> PCL (poly-ε-caprolactone) nanofibrous scaffolds with adhered liposomes were prepared and tested as a possible drug delivery system for various synthetic growth factors. TGFβ, bFGF, and IGF-I have been shown to increase hMSC (human mesenchymal stem cells) proliferation and to induce hMSC differentiation. Functionalized PCL nanofibers were prepared with synthetic growth factors encapsulated in liposomes adhered to them in three different concentrations. Other samples contained PCL nanofibers with adhered, free synthetic growth factors. The synthetic growth factors free medium served as a control. The interaction of liposomes with the PCL nanofibers was visualized by SEM, and the release kinetics were determined by ELISA testing. The potential of liposomes, immobilized on the biodegradable scaffolds, as a delivery system for synthetic growth factors, and as a suitable system for MSCs adhesion, proliferation and differentiation in vitro was evaluated by MTS assay, dsDNA amount determination, confocal microscopy, flow cytometry and real-time PCR. The results showed that the growth factors adhered to the PCL nanofibers stimulated cell proliferation mainly up to day 11 and that subsequently their effect was lower. By contrast, the release of the lowest concentration of growth factors from liposomes resulted in gradual proliferation of MSCs throughout the experiment. Moreover, liposomes, as well as free growth factors, stimulated type II collagen production, which was confirmed by immunohistochemical staining using monoclonal antibody against type II collagen. The results of this study indicate that growth factors enriched liposomes adhered to surface of PCL nanofibers could be useful as a drug delivery instrument for application in short timescales, be combined with nanofiber scaffolds to promote local and persistent delivery while mimicking the local microenvironment. This work was supported by project LO1508 from the Ministry of Education, Youth and Sports of the Czech Republic <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title="drug delivery">drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=growth%20factors" title=" growth factors"> growth factors</a>, <a href="https://publications.waset.org/abstracts/search?q=hMSC" title=" hMSC"> hMSC</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=nanofibres" title=" nanofibres"> nanofibres</a> </p> <a href="https://publications.waset.org/abstracts/52564/poly-e-caprolactone-nanofibers-with-synthetic-growth-factor-enriched-liposomes-as-controlled-drug-delivery-system" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/52564.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">290</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">63</span> Thermodynamic Properties of Calcium-Containing DPPA and DPPC Liposomes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tamaz%20Mdzinarashvili">Tamaz Mdzinarashvili</a>, <a href="https://publications.waset.org/abstracts/search?q=Mariam%20Khvedelidze"> Mariam Khvedelidze</a>, <a href="https://publications.waset.org/abstracts/search?q=Eka%20Shekiladze"> Eka Shekiladze</a>, <a href="https://publications.waset.org/abstracts/search?q=Salome%20Chinchaladze"> Salome Chinchaladze</a>, <a href="https://publications.waset.org/abstracts/search?q=Mariam%20Mdzinarashvili"> Mariam Mdzinarashvili</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The work is about the preparation of calcium-containing 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA) and their calorimetric study. In order to prepare these complex liposomes, for the first stage it is necessary for ligands and lipids to directly interact, followed by the addition of pH-buffered water or solvent at temperatures slightly above the liposome phase transition temperature. The resulting mixture is briefly but vigorously shaken and then transformed into liposomes of the desired size using an extruder. Particle sizing and calorimetry were used to evaluate liposome formation. We determined the possible structure of calcium-containing liposomes made by our new technology and determined their thermostability. The paper provides calculations showing how many phospholipid molecules are required to make a 200 nm diameter liposome. Calculations showed that 33x10³ lipid molecules are needed to prepare one DPPA and DPPC liposome. Based on the calorimetric experiments, we determined that the structure of uncomplexed DPPA liposomes is unilaminar (one double layer), while DPPC liposome is a nanoparticle with a multilaminar (multilayer) structure. This was determined by the cooperativity of the heat absorption peak. Calorimetric studies of calcium liposomes made by our technology showed that calcium ions are placed in the multilaminar structure of the DPPC liposome. Calcium ions also formed a complex in the DPPA liposome structure, moreover, calcium made the DPPA liposome multilaminar, since the cooperative narrow heat absorption peak was transformed into a three-peak heat absorption peak. Since both types of liposomes in complex with calcium ions present a multilaminar structure, where the number of lipid heads in one particle is large, the number of calcium ions in one particle will also be increased. That makes it possible to use these nanoparticles as transporters of a large amount of calcium ions in a living organism. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=calcium" title="calcium">calcium</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=thermodynamic%20parameters" title=" thermodynamic parameters"> thermodynamic parameters</a>, <a href="https://publications.waset.org/abstracts/search?q=calorimetry" title=" calorimetry"> calorimetry</a> </p> <a href="https://publications.waset.org/abstracts/187071/thermodynamic-properties-of-calcium-containing-dppa-and-dppc-liposomes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/187071.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">37</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">62</span> Preparation of Pegylated Interferon Alpha-2b with High Antiviral Activity Using Linear 20 KDa Polyethylene Glycol Derivative</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ehab%20El-Dabaa">Ehab El-Dabaa</a>, <a href="https://publications.waset.org/abstracts/search?q=Omnia%20Ali"> Omnia Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Abd%20El-Hady"> Mohamed Abd El-Hady</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Osman"> Ahmed Osman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Recombinant human interferon alpha 2 (rhIFN-α2) is FDA approved for treatment of some viral and malignant diseases. Approved pegylated rhIFN-α2 drugs have highly improved pharmacokinetics, pharmacodynamics and therapeutic efficiency compared to native protein. In this work, we studied the pegylation of purified properly refolded rhIFN-α2b using linear 20kDa PEG-NHS (polyethylene glycol- N-hydroxysuccinimidyl ester) to prepare pegylated rhIFN-α2b with high stability and activity. The effect of different parameters like rhIFN-α2b final concentration, pH, rhIFN-α2b/PEG molar ratios and reaction time on the efficiency of pegylation (high percentage of monopegylated rhIFN-α2b) have been studied in small scale (100µl) pegylation reaction trials. Study of the percentages of different components of these reactions (mono, di, polypegylated rhIFN-α2b and unpegylated rhIFN-α2b) indicated that 2h is optimum time to complete the reaction. The pegylation efficiency increased at pH 8 (57.9%) by reducing the protein concentration to 1mg/ml and reducing the rhIFN-α2b/PEG ratio to 1:2. Using larger scale pegylation reaction (65% pegylation efficiency), ion exchange chromatography method has been optimized to prepare and purify the monopegylated rhIFN-α2b with high purity (96%). The prepared monopegylated rhIFN-α2b had apparent Mwt of approximately 65 kDa and high in vitro antiviral activity (2.1x10⁷ ± 0.8 x10⁷ IU/mg). Although it retained approximately 8.4 % of the antiviral activity of the unpegylated rhIFN-α2b, its activity is high compared to other pegylated rhIFN-α2 developed by using similar approach or higher molecular weight branched PEG. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antiviral%20activity" title="antiviral activity">antiviral activity</a>, <a href="https://publications.waset.org/abstracts/search?q=rhIFN-%CE%B12b" title=" rhIFN-α2b"> rhIFN-α2b</a>, <a href="https://publications.waset.org/abstracts/search?q=pegylation" title=" pegylation"> pegylation</a>, <a href="https://publications.waset.org/abstracts/search?q=pegylation%20efficiency" title=" pegylation efficiency"> pegylation efficiency</a> </p> <a href="https://publications.waset.org/abstracts/82826/preparation-of-pegylated-interferon-alpha-2b-with-high-antiviral-activity-using-linear-20-kda-polyethylene-glycol-derivative" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/82826.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">177</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">61</span> Polymersomes in Drug Delivery: A Comparative Review with Liposomes and Micelles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Salma%20E.%20Ahmed">Salma E. Ahmed</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Since the mid 50’s, enormous attention has been paid towards nanocarriers and their applications in drug and gene delivery. Among these vesicles, liposomes and micelles have been heavily investigated due to their many advantages over other types. Liposomes, for instance, are mostly distinguished by their ability to encapsulate hydrophobic, hydrophilic and amphiphilic drugs. Micelles, on the other hand, are self-assembled shells of lipids, amphiphilic or oppositely charged block copolymers that, once exposed to aqueous media, can entrap hydrophobic agents, and possess prolonged circulation in the bloodstream. Both carriers are considered compatible and biodegradable. Nevertheless, they have limited stabilities, chemical versatilities, and drug encapsulation efficiencies. In order to overcome these downsides, strategies for optimizing a novel drug delivery system that has the architecture of liposomes and polymeric characteristics of micelles have been evolved. Polymersomes are vehicles with fluidic cores and hydrophobic shells that are protected and isolated from the aqueous media by the hydrated hydrophilic brushes which give the carrier its distinctive polymeric bilayer shape. Similar to liposomes, this merit enables the carrier to encapsulate a wide range of agents, despite their affinities and solubilities in water. Adding to this, the high molecular weight of the amphiphiles that build the body of the polymersomes increases their colloidal and chemical stabilities and reduces the permeability of the polymeric membranes, which makes the vesicles more protective to the encapsulated drug. These carriers can also be modified in ways that make them responsive when targeted or triggered, by manipulating their composition and attaching moieties and conjugates to the body of the carriers. These appealing characteristics, in addition to the ease of synthesis, gave the polymersomes greater potentials in the area of drug delivery. Thus, their design and characterization, in comparison with liposomes and micelles, are briefly reviewed in this work. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=controlled%20release" title="controlled release">controlled release</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=micelles" title=" micelles"> micelles</a>, <a href="https://publications.waset.org/abstracts/search?q=polymersomes" title=" polymersomes"> polymersomes</a>, <a href="https://publications.waset.org/abstracts/search?q=targeting" title=" targeting"> targeting</a> </p> <a href="https://publications.waset.org/abstracts/67371/polymersomes-in-drug-delivery-a-comparative-review-with-liposomes-and-micelles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/67371.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">195</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">60</span> Double Liposomes Based Dual Drug Delivery System for Effective Eradication of Helicobacter pylori</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yuvraj%20Singh%20Dangi">Yuvraj Singh Dangi</a>, <a href="https://publications.waset.org/abstracts/search?q=Brajesh%20Kumar%20Tiwari"> Brajesh Kumar Tiwari</a>, <a href="https://publications.waset.org/abstracts/search?q=Ashok%20Kumar%20Jain"> Ashok Kumar Jain</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamta%20Prasad%20Namdeo"> Kamta Prasad Namdeo</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The potential use of liposomes as drug carriers by i.v. injection is limited by their low stability in blood stream. Firstly, phospholipid exchange and transfer to lipoproteins, mainly HDL destabilizes and disintegrates liposomes with subsequent loss of content. To avoid the pain associated with injection and to obtain better patient compliance studies concerning various dosage forms, have been developed. Conventional liposomes (unilamellar and multilamellar) have certain drawbacks like low entrapment efficiency, stability and release of drug after single breach in external membrane, have led to the new type of liposomal systems. The challenge has been successfully met in the form of Double Liposomes (DL). DL is a recently developed type of liposome, consisting of smaller liposomes enveloped in lipid bilayers. The outer lipid layer of DL can protect inner liposomes against various enzymes, therefore DL was thought to be more effective than ordinary liposomes. This concept was also supported by in vitro release characteristics i.e. DL formation inhibited the release of drugs encapsulated in inner liposomes. DL consists of several small liposomes encapsulated in large liposomes, i.e., multivesicular vesicles (MVV), therefore, DL should be discriminated from ordinary classification of multilamellar vesicles (MLV), large unilamellar vesicles (LUV), small unilamellar vesicles (SUV). However, for these liposomes, the volume of inner phase is small and loading volume of water-soluble drugs is low. In the present study, the potential of phosphatidylethanolamine (PE) lipid anchored double liposomes (DL) to incorporate two drugs in a single system is exploited as a tool to augment the H. pylori eradication rate. Preparation of DL involves two steps, first formation of primary (inner) liposomes by thin film hydration method containing one drug, then addition of suspension of inner liposomes on thin film of lipid containing the other drug. The success of formation of DL was characterized by optical and transmission electron microscopy. Quantitation of DL-bacterial interaction was evaluated in terms of percent growth inhibition (%GI) on reference strain of H. pylori ATCC 26695. To confirm specific binding efficacy of DL to H. pylori PE surface receptor we performed an agglutination assay. Agglutination in DL treated H. pylori suspension suggested selectivity of DL towards the PE surface receptor of H. pylori. Monotherapy is generally not recommended for treatment of a H. pylori infection due to the danger of development of resistance and unacceptably low eradication rates. Therefore, combination therapy with amoxicillin trihydrate (AMOX) as anti-H. pylori agent and ranitidine bismuth citrate (RBC) as antisecretory agent were selected for the study with an expectation that this dual-drug delivery approach will exert acceptable anti-H. pylori activity. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Helicobacter%20pylorI" title="Helicobacter pylorI">Helicobacter pylorI</a>, <a href="https://publications.waset.org/abstracts/search?q=amoxicillin%20trihydrate" title=" amoxicillin trihydrate"> amoxicillin trihydrate</a>, <a href="https://publications.waset.org/abstracts/search?q=Ranitidine%20Bismuth%20citrate" title=" Ranitidine Bismuth citrate"> Ranitidine Bismuth citrate</a>, <a href="https://publications.waset.org/abstracts/search?q=phosphatidylethanolamine" title=" phosphatidylethanolamine"> phosphatidylethanolamine</a>, <a href="https://publications.waset.org/abstracts/search?q=multi%20vesicular%20systems" title=" multi vesicular systems"> multi vesicular systems</a> </p> <a href="https://publications.waset.org/abstracts/56355/double-liposomes-based-dual-drug-delivery-system-for-effective-eradication-of-helicobacter-pylori" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56355.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">207</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">59</span> Calcein Release from Liposomes Mediated by Phospholipase A₂ Activity: Effect of Cholesterol and Amphipathic Di and Tri Blocks Copolymers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Marco%20Soto-Arriaza">Marco Soto-Arriaza</a>, <a href="https://publications.waset.org/abstracts/search?q=Eduardo%20Cena-Ahumada"> Eduardo Cena-Ahumada</a>, <a href="https://publications.waset.org/abstracts/search?q=Jaime%20Melendez-Rojel"> Jaime Melendez-Rojel</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Liposomes have been widely used as a model of lipid bilayer to study the physicochemical properties of biological membrane, encapsulation, transport and release of different molecules. Furthermore, extensive research has focused on improving the efficiency in the transport of drugs, developing tools that improve the release of the encapsulated drug from liposomes. In this context, the enzymatic activity of PLA₂, despite having been shown to be an effective tool to promote the release of drugs from liposomes, is still an open field of research. Aim: The aim of the present study is to explore the effect of cholesterol (Cho) and amphipathic di- and tri-block copolymers, on calcein release mediated by enzymatic activity of PLA2 in Dipalmitoylphosphatidylcholine (DPPC) liposomes under physiological conditions. Methods: Different dispersions of DPPC, cholesterol, di-block POE₄₅-PCL₅₂ or tri-block PCL₁₂-POE₄₅-PCL₁₂ were prepared by the extrusion method after five freezing/thawing cycles; in Phosphate buffer 10mM pH 7.4 in presence of calcein. DPPC liposomes/Calcein were centrifuged at 15000rpm 10 min to separate free calcein. Enzymatic activity assays of PLA₂ were performed at 37°C using the TBS buffer pH 7.4. The size distribution, polydispersity, Z-potential and Calcein encapsulation of DPPC liposomes was monitored. Results: PLA₂ activity showed a slower kinetic of calcein release up to 20 mol% of cholesterol, evidencing a minimum at 10 mol% and then a maximum at 18 mol%. Regardless of the percentage of cholesterol, up to 18 mol% a one-hundred percentage release of calcein was observed. At higher cholesterol concentrations, PLA₂ showed to be inefficient or not to be involved in calcein release. In assays where copolymers were added in a concentration lower than their cmc, a similar behavior to those showed in the presence of Cho was observed, that is a slower kinetic in calcein release. In both experimental approaches, a one-hundred percentage of calcein release was observed. PLA₂ was shown to be sensitive to the 4-(4-Octadecylphenyl)-4-oxobutenoic acid inhibitor and calcium, reducing the release of calcein to 0%. Cell viability of HeLa cells decreased 7% in the presence of DPPC liposomes after 3 hours of incubation and 17% and 23% at 5 and 15 hours, respectively. Conclusion: Calcein release from DPPC liposomes, mediated by PLA₂ activity, depends on the percentage of cholesterol and the presence of copolymers. Both, cholesterol up to 20 mol% and copolymers below it cmc could be applied to the regulation of the kinetics of antitumoral drugs release without inducing cell toxicity per se. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=amphipathic%20copolymers" title="amphipathic copolymers">amphipathic copolymers</a>, <a href="https://publications.waset.org/abstracts/search?q=calcein%20release" title=" calcein release"> calcein release</a>, <a href="https://publications.waset.org/abstracts/search?q=cholesterol" title=" cholesterol"> cholesterol</a>, <a href="https://publications.waset.org/abstracts/search?q=DPPC%20liposome" title=" DPPC liposome"> DPPC liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=phospholipase%20A%E2%82%82" title=" phospholipase A₂"> phospholipase A₂</a> </p> <a href="https://publications.waset.org/abstracts/138744/calcein-release-from-liposomes-mediated-by-phospholipase-a2-activity-effect-of-cholesterol-and-amphipathic-di-and-tri-blocks-copolymers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/138744.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">163</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">58</span> Development of Nanostructrued Hydrogel for Spatial and Temporal Controlled Release of Active Compounds</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shaker%20Alsharif">Shaker Alsharif</a>, <a href="https://publications.waset.org/abstracts/search?q=Xavier%20Banquy"> Xavier Banquy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Controlled drug delivery technology represents one of the most rapidly advancing areas of science in which chemists and chemical engineers are contributing to human health care. Such delivery systems provide numerous advantages compared to conventional dosage forms including improved efficacy, and improved patient compliance and convenience. Such systems often use synthetic polymers as carriers for the drugs. As a result, treatments that would not otherwise be possible are now in conventional use. The role of bilayered vesicles as efficient carriers for drugs, vaccines, diagnostic agents and other bioactive agents have led to a rapid advancement in the liposomal drug delivery system. Moreover, the site avoidance and site-specific drug targeting therapy could be achieved by formulating a liposomal product, so as to reduce the cytotoxicity of many potent therapeutic agents. Our project focuses on developing and building hydrogel with nanoinclusion of liposomes loaded with active compounds such as proteins and growth factors able to release them in a controlled fashion. In order to achieve that, we synthesize several liposomes of two different phospholipids concentrations encapsulating model drug. Then, formulating hydrogel with specific mechanical properties embedding the liposomes to manage the release of active compound. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=controlled%20release" title="controlled release">controlled release</a>, <a href="https://publications.waset.org/abstracts/search?q=hydrogel" title=" hydrogel"> hydrogel</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=active%20compounds" title=" active compounds"> active compounds</a> </p> <a href="https://publications.waset.org/abstracts/33224/development-of-nanostructrued-hydrogel-for-spatial-and-temporal-controlled-release-of-active-compounds" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/33224.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">447</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">57</span> Tripeptide Inhibitor: The Simplest Aminogenic PEGylated Drug against Amyloid Beta Peptide Fibrillation</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sutapa%20Som%20Chaudhury">Sutapa Som Chaudhury</a>, <a href="https://publications.waset.org/abstracts/search?q=Chitrangada%20Das%20Mukhopadhyay"> Chitrangada Das Mukhopadhyay</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Alzheimer’s disease is a well-known form of dementia since its discovery in 1906. Current Food and Drug Administration approved medications e.g. cholinesterase inhibitors, memantine offer modest symptomatic relief but do not play any role in disease modification or recovery. In last three decades many small molecules, chaperons, synthetic peptides, partial β-secretase enzyme blocker have been tested for the development of a drug against Alzheimer though did not pass the 3rd clinical phase trials. Here in this study, we designed a PEGylated, aminogenic, tripeptidic polymer with two different molecular weights based on the aggregation prone amino acid sequence 17-20 in amyloid beta (Aβ) 1-42. Being conjugated with poly-ethylene glycol (PEG) which self-assembles into hydrophilic nanoparticles, these PEGylated tripeptides constitute a very good drug delivery system crossing the blood brain barrier while the peptide remains protected from proteolytic degradation and non-specific protein interactions. Moreover, being completely aminogenic they would not raise any side effects. These peptide inhibitors were evaluated for their effectiveness against Aβ42 fibrillation at an early stage of oligomer to fibril formation as well as preformed fibril clearance via Thioflavin T (ThT) assay, dynamic light scattering analyses, atomic force microscopy and scanning electron microscopy. The inhibitors were proved to be safe at a higher concentration of 20µM by the reduction assay of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye. Moreover, SHSY5Y neuroblastoma cells have shown a greater survivability when treated with the inhibitors following Aβ42 fibril and oligomer treatment as compared with the control Aβ42 fibril and/or oligomer treated neuroblastoma cells. These make the peptidic inhibitors a promising compound in the aspect of the discovery of alternative medication for Alzheimer’s disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alzheimer%E2%80%99s%20disease" title="Alzheimer’s disease">Alzheimer’s disease</a>, <a href="https://publications.waset.org/abstracts/search?q=alternative%20medication" title=" alternative medication"> alternative medication</a>, <a href="https://publications.waset.org/abstracts/search?q=amyloid%20beta" title=" amyloid beta"> amyloid beta</a>, <a href="https://publications.waset.org/abstracts/search?q=PEGylated%20peptide" title=" PEGylated peptide"> PEGylated peptide</a> </p> <a href="https://publications.waset.org/abstracts/74111/tripeptide-inhibitor-the-simplest-aminogenic-pegylated-drug-against-amyloid-beta-peptide-fibrillation" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/74111.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">209</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">56</span> Fabrication and Characterization of Folic Acid-Grafted-Thiomer Enveloped Liposomes for Enhanced Oral Bioavailability of Docetaxel </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Farhan%20Sohail">Farhan Sohail</a>, <a href="https://publications.waset.org/abstracts/search?q=Gul%20Shahnaz%20Irshad%20Hussain"> Gul Shahnaz Irshad Hussain</a>, <a href="https://publications.waset.org/abstracts/search?q=Shoaib%20Sarwar"> Shoaib Sarwar</a>, <a href="https://publications.waset.org/abstracts/search?q=Ibrahim%20Javed"> Ibrahim Javed</a>, <a href="https://publications.waset.org/abstracts/search?q=Zajif%20Hussain"> Zajif Hussain</a>, <a href="https://publications.waset.org/abstracts/search?q=Akhtar%20Nadhman"> Akhtar Nadhman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The present study was aimed to develop a hybrid nanocarrier (NC) system with enhanced membrane permeability, bioavailability and targeted delivery of Docetaxel (DTX) in breast cancer. Hybrid NC’s based on folic acid (FA) grafted thiolated chitosan (TCS) enveloped liposomes were prepared with DTX and evaluated in-vitro and in-vivo for their enhanced permeability and bioavailability. Physicochemical characterization of NC’s including particle size, morphology, zeta potential, FTIR, DSC, PXRD, encapsulation efficiency and drug release from NC’s was determined in vitro. Permeation enhancement and p-gp inhibition were performed through everted sac method on freshly excised rat intestine which indicated that permeation was enhanced 5 times as compared to pure DTX and the hybrid NC’s were strongly able to inhibit the p-gp activity as well. In-vitro cytotoxicity and tumor targeting was done using MDA-MB-231 cell line. The stability study of the formulations performed for 3 months showed the improved stability of FA-TCS enveloped liposomes in terms of its particles size, zeta potential and encapsulation efficiency as compared to TCS NP’s and liposomes. The pharmacokinetic study was performed in vivo using rabbits. The oral bioavailability and AUC0-96 was increased 10.07 folds with hybrid NC’s as compared to positive control. Half-life (t1/2) was increased 4 times (58.76 hrs) as compared to positive control (17.72 hrs). Conclusively, it is suggested that FA-TCS enveloped liposomes have strong potential to enhance permeability and bioavailability of hydrophobic drugs after oral administration and tumor targeting. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=docetaxel" title="docetaxel">docetaxel</a>, <a href="https://publications.waset.org/abstracts/search?q=coated%20liposome" title=" coated liposome"> coated liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=permeation%20enhancement" title=" permeation enhancement"> permeation enhancement</a>, <a href="https://publications.waset.org/abstracts/search?q=oral%20bioavailability" title=" oral bioavailability"> oral bioavailability</a> </p> <a href="https://publications.waset.org/abstracts/45575/fabrication-and-characterization-of-folic-acid-grafted-thiomer-enveloped-liposomes-for-enhanced-oral-bioavailability-of-docetaxel" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/45575.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">408</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">55</span> Development of Ketorolac Tromethamine Encapsulated Stealth Liposomes: Pharmacokinetics and Bio Distribution</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yasmin%20Begum%20Mohammed">Yasmin Begum Mohammed</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Ketorolac tromethamine (KTM) is a non-steroidal anti-inflammatory drug with a potent analgesic and anti-inflammatory activity due to prostaglandin related inhibitory effect of drug. It is a non-selective cyclo-oxygenase inhibitor. The drug is currently used orally and intramuscularly in multiple divided doses, clinically for the management arthritis, cancer pain, post-surgical pain, and in the treatment of migraine pain. KTM has short biological half-life of 4 to 6 hours, which necessitates frequent dosing to retain the action. The frequent occurrence of gastrointestinal bleeding, perforation, peptic ulceration, and renal failure lead to the development of other drug delivery strategies for the appropriate delivery of KTM. The ideal solution would be to target the drug only to the cells or tissues affected by the disease. Drug targeting could be achieved effectively by liposomes that are biocompatible and biodegradable. The aim of the study was to develop a parenteral liposome formulation of KTM with improved efficacy while reducing side effects by targeting the inflammation due to arthritis. PEG-anchored (stealth) and non-PEG-anchored liposomes were prepared by thin film hydration technique followed by extrusion cycle and characterized for in vitro and in vivo. Stealth liposomes (SLs) exhibited increase in percent encapsulation efficiency (94%) and 52% percent of drug retention during release studies in 24 h with good stability for a period of 1 month at -20°C and 4°C. SLs showed about maximum 55% of edema inhibition with significant analgesic effect. SLs produced marked differences over those of non-SL formulations with an increase in area under plasma concentration time curve, t₁/₂, mean residence time, and reduced clearance. 0.3% of the drug was detected in arthritic induced paw with significantly reduced drug localization in liver, spleen, and kidney for SLs when compared to other conventional liposomes. Thus SLs help to increase the therapeutic efficacy of KTM by increasing the targeting potential at the inflammatory region. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodistribution" title="biodistribution">biodistribution</a>, <a href="https://publications.waset.org/abstracts/search?q=ketorolac%20tromethamine" title=" ketorolac tromethamine"> ketorolac tromethamine</a>, <a href="https://publications.waset.org/abstracts/search?q=stealth%20liposomes" title=" stealth liposomes"> stealth liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=thin%20film%20hydration%20technique" title=" thin film hydration technique"> thin film hydration technique</a> </p> <a href="https://publications.waset.org/abstracts/124164/development-of-ketorolac-tromethamine-encapsulated-stealth-liposomes-pharmacokinetics-and-bio-distribution" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/124164.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">295</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">54</span> Surface Acoustic Waves Nebulisation of Liposomes Manufactured in situ for Pulmonary Drug Delivery</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=X.%20King">X. King</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20Nazarzadeh"> E. Nazarzadeh</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Reboud"> J. Reboud</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Cooper"> J. Cooper</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Pulmonary diseases, such as asthma, are generally treated by the inhalation of aerosols that has the advantage of reducing the off-target (e.g., toxicity) effects associated with systemic delivery in blood. Effective respiratory drug delivery requires a droplet size distribution between 1 and 5 µm. Inhalation of aerosols with wide droplet size distribution, out of this range, results in deposition of drug in not-targeted area of the respiratory tract, introducing undesired side effects on the patient. In order to solely deliver the drug in the lower branches of the lungs and release it in a targeted manner, a control mechanism to produce the aerosolized droplets is required. To regulate the drug release and to facilitate the uptake from cells, drugs are often encapsulated into protective liposomes. However, a multistep process is required for their formation, often performed at the formulation step, therefore limiting the range of available drugs or their shelf life. Using surface acoustic waves (SAWs), a pulmonary drug delivery platform was produced, which enabled the formation of defined size aerosols and the formation of liposomes in situ. SAWs are mechanical waves, propagating along the surface of a piezoelectric substrate. They were generated using an interdigital transducer on lithium niobate with an excitation frequency of 9.6 MHz at a power of 1W. Disposable silicon superstrates were etched using photolithography and dry etch processes to create an array of cylindrical through-holes with different diameters and pitches. Superstrates were coupled with the SAW substrate through water-based gel. As the SAW propagates on the superstrate, it enables nebulisation of a lipid solution deposited onto it. The cylindrical cavities restricted the formation of large drops in the aerosol, while at the same time unilamellar liposomes were created. SAW formed liposomes showed a higher monodispersity compared to the control sample, as well as displayed, a faster production rate. To test the aerosol’s size, dynamic light scattering and laser diffraction methods were used, both showing the size control of the aerosolised particles. The use of silicon superstate with cavity size of 100-200 µm, produced an aerosol with a mean droplet size within the optimum range for pulmonary drug delivery, containing the liposomes in which the medicine could be loaded. Additionally, analysis of liposomes with Cryo-TEM showed formation of vesicles with narrow size distribution between 80-100 nm and optimal morphology in order to be used for drug delivery. Encapsulation of nucleic acids in liposomes through the developed SAW platform was also investigated. In vitro delivery of siRNA and DNA Luciferase were achieved using A549 cell line, lung carcinoma from human. In conclusion, SAW pulmonary drug delivery platform was engineered, in order to combine multiple time consuming steps (formation of liposomes, drug loading, nebulisation) into a unique platform with the aim of specifically delivering the medicament in a targeted area, reducing the drug’s side effects. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acoustics" title="acoustics">acoustics</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title=" drug delivery"> drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=surface%20acoustic%20waves" title=" surface acoustic waves"> surface acoustic waves</a> </p> <a href="https://publications.waset.org/abstracts/84617/surface-acoustic-waves-nebulisation-of-liposomes-manufactured-in-situ-for-pulmonary-drug-delivery" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/84617.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">124</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">53</span> Synergistic Studies of Liposomes of Clove and Cinnamon Oil in Oral Health Care</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sandhya%20Parameswaran">Sandhya Parameswaran</a>, <a href="https://publications.waset.org/abstracts/search?q=Prajakta%20Dhuri"> Prajakta Dhuri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Despite great improvements in health care, the world oral health report states that dental problems still persist, particularly among underprivileged groups in both developing and developed countries. Dental caries and periodontal diseases are identified as the most important oral health problems globally. Acidic foods and beverages can affect natural teeth, and chronic exposure often leads to the development of dental erosion, abrasion, and decay. In recent years, there has been an increased interest toward essential oils. These are secondary metabolites and possess antibacterial, antifungal and antioxidant properties. Essential oils are volatile and chemically unstable in the presence of air, light, moisture and high temperature. Hence many novel methods like a liposomal encapsulation of oils have been introduced to enhance the stability and bioavailability. This research paper focuses on two essential oils, clove and cinnamon oil. Clove oil was obtained from Syzygium aromaticum Linn using clavengers apparatus. It contains eugenol and β caryophyllene. Cinnamon oil, from the barks of Cinnamomum cassia, contains cinnamaldehyde, The objective of the current research was to develop a liposomal carrier system containing clove and cinnamon oil and study their synergistic activity against dental pathogens when formulated as a gel. Methodology: The essential oil were first tested for their antimicrobial activity against dental pathogens, Lactobacillus acidophillus (MTCC No. 10307, MRS broth) and Streptococcus Mutans (MTCC No .890, Brain Heart Infusion agar). The oils were analysed by UV spectroscopy for eugenol and cinnamaldehyde content. Standard eugenol was linear between 5ppm to 25ppm at 282nm and standard cinnamaldehde from 1ppm to 5pmm at 284nm. The concentration of eugenol in clove oil was found to be 62.65 % w/w, and that of cinnamaldehyde was found to be 5.15%s w/w. The oils were then formulated into liposomes. Liposomes were prepared by thin film hydration method using Phospholipid, Cholesterol, and other oils dissolved in a chloroform methanol (3:1) mixture. The organic solvent was evaporated in a rotary evaporator above lipid transition temperature. The film was hydrated with phosphate buffer (pH 5.5).The various batches of liposomes were characterized and compared for their size, loading rate, encapsulation efficiency and morphology. The prepared liposomes when evaluated for entrapment efficiency showed 65% entrapment for clove and 85% for cinnamon oil. They were also tested for their antimicrobial activity against dental pathogens and their synergistic activity studied. Based on the activity and the entrapment efficiency the amount of liposomes required to prepare 1gm of the gel was calculated. The gel was prepared using a simple ointment base and contained 0.56% of cinnamon and clove liposomes. A simultaneous method of analysis for eugenol and cinnamaldehyde.was then developed using HPLC. The prepared gels were then studied for their stability as per ICH guidelines. Conclusion: It was found that liposomes exhibited spherical shaped vesicles and protected the essential oil from degradation. Liposomes, therefore, constitute a suitable system for encapsulation of volatile, unstable essential oil constituents. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cinnamon%20oil" title="cinnamon oil">cinnamon oil</a>, <a href="https://publications.waset.org/abstracts/search?q=clove%20oil" title=" clove oil"> clove oil</a>, <a href="https://publications.waset.org/abstracts/search?q=dental%20caries" title=" dental caries"> dental caries</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a> </p> <a href="https://publications.waset.org/abstracts/72986/synergistic-studies-of-liposomes-of-clove-and-cinnamon-oil-in-oral-health-care" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/72986.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">194</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">52</span> Study of the Formation Mechanism of Dipalmitoylphosphatidylcholine Liposomes and Calcium Ion Complexes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=T.%20Mdzinarashvili">T. Mdzinarashvili</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Khvedelidze"> M. Khvedelidze</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20Shekiladze"> E. Shekiladze</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Chinchaladze"> S. Chinchaladze</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mdzinarashvili"> M. Mdzinarashvili</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study of the possible interaction between calcium ions and lipids is of great importance for the studies of complexes of calcium drug-carrying nanoparticles. We prepared calcium-containing complex liposomes from Dipalmitoylphosphatidylcholine (DPPC) lipids and studied their thermodynamic properties. In calorimetric studies, we determined that the phase transition temperature of these complexes is close to 420 C. It was shown that both hydrophobic and hydrophilic connections take part in the formation of calcium nanoparticles. We were interested in hydrophilic bonds represented by hydrogen bonds. We have shown that these hydrogen bonds are formed between the phospholipid heads, and the main contributor is the oxygen atoms in the phosphoric acid residues. In addition, based on the amount of heat absorbed during the breaking of hydrogen bonds formed between calcium-containing nanoparticle complexes, it can be concluded that the hydrogen atoms in the head of DPPC lipids form hydrogen bonds between P=O and P-O groups of phosphate. The energy of heat absorption measured by the calorimeter is of the order obtained by breaking the hydrogen bonds we have specified. Thus, we conclude that our approach to the model of liposome formation from lipids is correct. As for calcium atoms - due to the fact that it is present in the form of positive ions in the liposome, they will connect only with negatively charged phosphorus ions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=DPPC" title="DPPC">DPPC</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=calcium" title=" calcium"> calcium</a>, <a href="https://publications.waset.org/abstracts/search?q=complex%20nanoparticles" title=" complex nanoparticles"> complex nanoparticles</a> </p> <a href="https://publications.waset.org/abstracts/154573/study-of-the-formation-mechanism-of-dipalmitoylphosphatidylcholine-liposomes-and-calcium-ion-complexes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154573.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">117</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">51</span> Layersomes for Oral Delivery of Amphotericin B</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=A.%20C.%20Rana">A. C. Rana</a>, <a href="https://publications.waset.org/abstracts/search?q=Abhinav%20Singh%20Rana"> Abhinav Singh Rana</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Layer by layer coating of biocompatible polyelectrolytes converts the liposomes into stable version i.e 'layersomes'. This system was further used to deliver the Amphotericin B through the oral route. Extensive optimization of different process variables resulted in the formation of layersomes with the particle size of 238.4±5.1, PDI of 0.24±0.16, the zeta potential of 34.6±1.3, and entrapment efficiency of 71.3±1.2. TEM analysis further confirmed the formation of spherical particles. Trehalose (10% w/w) resulted in the formation of fluffy and easy to redisperse cake in freeze dried layersomes. Controlled release up to 50 % within 24 h was observed in the case of layersomes. The layersomes were found stable in simulated biological fluids and resulted in the 3.59 fold higher bioavailability in comparison to free Amp-B. Furthermore, the developed formulation was found to be safe in comparison to Fungizone as indicated by blood urea nitrogen (BUN) and creatinine level. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=amphotericin%20B" title="amphotericin B">amphotericin B</a>, <a href="https://publications.waset.org/abstracts/search?q=layersomes" title=" layersomes"> layersomes</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=toxicity" title=" toxicity"> toxicity</a> </p> <a href="https://publications.waset.org/abstracts/16358/layersomes-for-oral-delivery-of-amphotericin-b" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16358.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">527</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">50</span> Green Synthesis of Nano Liposomes Containing Berberine Chlorideagainst Leishmania major</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ali%20Fattahi%20Bafghi">Ali Fattahi Bafghi</a>, <a href="https://publications.waset.org/abstracts/search?q=Abolghasem%20Siyadatpanah"> Abolghasem Siyadatpanah</a>, <a href="https://publications.waset.org/abstracts/search?q=Farzaneh%20Mirzaei"> Farzaneh Mirzaei</a>, <a href="https://publications.waset.org/abstracts/search?q=Fahimeh%20Pournasir"> Fahimeh Pournasir</a>, <a href="https://publications.waset.org/abstracts/search?q=Roghayeh%20Norouzi"> Roghayeh Norouzi</a>, <a href="https://publications.waset.org/abstracts/search?q=Maria%20De%20Lourdes%20Pereira"> Maria De Lourdes Pereira</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Leishmaniasis caused by Leishmania major is one of the main infectious diseases that affect populations in developing countries around the world. We assessed the effectiveness of berberine chloride nano-liposome (BcNLs) against L. major promastigotes in vitro. Nano-liposomal berberine chloride was prepared using the thin-film hydration method and characterized based on encapsulation efficiency, size, and zeta potential. Anti-Leishmania effect of different concentrations (0.05-60 µg/ml) of BcNLs as studied in L. major [MRHO/IR/75/ER] at 24, 48, and 72 h using the hemocytometer technique. Berberine chloride was successfully loaded into nano-liposomes with an encapsulation efficiency of 85.54%. The surface charge of nanoparticles is neutral, and the morphology of nano-liposomal berberine chloride is spherical without any agglomeration. Cell viability assay was performed on the HFF cell line to show the biocompatibility of liposome nanoparticles. IC50 of BcNPs at 24, 48, and 72 h against L. major were found to be 7.6, 5.96, and 3.19 µg/ml, respectively. BcNLs showed a significant anti-Leishmania effect and induced a better and more tangible effect on the survival of L. major promastigotes and could be suitable candidates for further investigation. The results showed that the BcNLs agent is effective against L. major promastigotes and may be a promising alternative to current treatments. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Leishmania%20major" title="Leishmania major">Leishmania major</a>, <a href="https://publications.waset.org/abstracts/search?q=berberine%20chloride" title=" berberine chloride"> berberine chloride</a>, <a href="https://publications.waset.org/abstracts/search?q=nano-liposomes" title=" nano-liposomes"> nano-liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=cutaneous%20leishmaniasis" title=" cutaneous leishmaniasis"> cutaneous leishmaniasis</a> </p> <a href="https://publications.waset.org/abstracts/136889/green-synthesis-of-nano-liposomes-containing-berberine-chlorideagainst-leishmania-major" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/136889.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">49</span> Liposome Loaded Polysaccharide Based Hydrogels: Promising Delayed Release Biomaterials</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=J.%20Desbrieres">J. Desbrieres</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Popa"> M. Popa</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20Peptu"> C. Peptu</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Bacaita"> S. Bacaita</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Because of their favorable properties (non-toxicity, biodegradability, mucoadhesivity etc.), polysaccharides were studied as biomaterials and as pharmaceutical excipients in drug formulations. These formulations may be produced in a wide variety of forms including hydrogels, hydrogel based particles (or capsules), films etc. In these formulations, the polysaccharide based materials are able to provide local delivery of loaded therapeutic agents but their delivery can be rapid and not easily time-controllable due to, particularly, the burst effect. This leads to a loss in drug efficiency and lifetime. To overcome the consequences of burst effect, systems involving liposomes incorporated into polysaccharide hydrogels may appear as a promising material in tissue engineering, regenerative medicine and drug loading systems. Liposomes are spherical self-closed structures, composed of curved lipid bilayers, which enclose part of the surrounding solvent into their structure. The simplicity of production, their biocompatibility, the size and similar composition of cells, the possibility of size adjustment for specific applications, the ability of hydrophilic or/and hydrophobic drug loading make them a revolutionary tool in nanomedicine and biomedical domain. Drug delivery systems were developed as hydrogels containing chitosan or carboxymethylcellulose (CMC) as polysaccharides and gelatin (GEL) as polypeptide, and phosphatidylcholine or phosphatidylcholine/cholesterol liposomes able to accurately control this delivery, without any burst effect. Hydrogels based on CMC were covalently crosslinked using glutaraldehyde, whereas chitosan based hydrogels were double crosslinked (ionically using sodium tripolyphosphate or sodium sulphate and covalently using glutaraldehyde). It has been proven that the liposome integrity is highly protected during the crosslinking procedure for the formation of the film network. Calcein was used as model active matter for delivery experiments. Multi-Lamellar vesicles (MLV) and Small Uni-Lamellar Vesicles (SUV) were prepared and compared. The liposomes are well distributed throughout the whole area of the film, and the vesicle distribution is equivalent (for both types of liposomes evaluated) on the film surface as well as deeper (100 microns) in the film matrix. An obvious decrease of the burst effect was observed in presence of liposomes as well as a uniform increase of calcein release that continues even at large time scales. Liposomes act as an extra barrier for calcein release. Systems containing MLVs release higher amounts of calcein compared to systems containing SUVs, although these liposomes are more stable in the matrix and diffuse with difficulty. This difference comes from the higher quantity of calcein present within the MLV in relation with their size. Modeling of release kinetics curves was performed and the release of hydrophilic drugs may be described by a multi-scale mechanism characterized by four distinct phases, each of them being characterized by a different kinetics model (Higuchi equation, Korsmeyer-Peppas model etc.). Knowledge of such models will be a very interesting tool for designing new formulations for tissue engineering, regenerative medicine and drug delivery systems. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=controlled%20and%20delayed%20release" title="controlled and delayed release">controlled and delayed release</a>, <a href="https://publications.waset.org/abstracts/search?q=hydrogels" title=" hydrogels"> hydrogels</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=polysaccharides" title=" polysaccharides"> polysaccharides</a> </p> <a href="https://publications.waset.org/abstracts/42555/liposome-loaded-polysaccharide-based-hydrogels-promising-delayed-release-biomaterials" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42555.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">226</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">48</span> Synthesis of Liposomal Vesicles by a Novel Supercritical Fluid Process</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Wen-Chyan%20Tsai">Wen-Chyan Tsai</a>, <a href="https://publications.waset.org/abstracts/search?q=Syed%20S.%20H.%20Rizvi"> Syed S. H. Rizvi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Organic solvent residues are always associated with liposomes produced by the traditional techniques like the thin film hydration and reverse phase evaporation methods, which limit the applications of these vesicles in the pharmaceutical, food and cosmetic industries. Our objective was to develop a novel and benign process of liposomal microencapsulation by using supercritical carbon dioxide (SC-CO2) as the sole phospholipid-dissolving medium and a green substitute for organic solvents. This process consists of supercritical fluid extraction followed by rapid expansion via a nozzle and automatic cargo suction. Lecithin and cholesterol mixed in 10:1 mass ratio were dissolved in SC-CO2 at 20 ± 0.5 MPa and 60 oC. After at least two hours of equilibrium, the lecithin/cholesterol-laden SC-CO2 was passed through a 1000-micron nozzle and immediately mixed with the cargo solution to form liposomes. Liposomal micro-encapsulation was conducted at three pressures (8.27, 12.41, 16.55 MPa), three temperatures (75, 83 and 90 oC) and two flow rates (0.25 ml/sec and 0.5 ml/sec). Liposome size, zeta potential and encapsulation efficiency were characterized as functions of the operating parameters. The average liposomal size varied from 400-500 nm to 1000-1200 nm when the pressure was increased from 8.27 to 16.55 MPa. At 12.41 MPa, 90 oC and 0.25 ml per second of 0.2 M glucose cargo loading rate, the highest encapsulation efficiency of 31.65 % was achieved. Under a confocal laser scanning microscope, large unilamellar vesicles and multivesicular vesicles were observed to make up a majority of the liposomal emulsion. This new approach is a rapid and continuous process for bulk production of liposomes using a green solvent. Based on the results to date, it is feasible to apply this technique to encapsulate hydrophilic compounds inside the aqueous core as well as lipophilic compounds in the phospholipid bilayers of the liposomes for controlled release, solubility improvement and targeted therapy of bioactive compounds. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=liposome" title="liposome">liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=micro%20encapsulation" title=" micro encapsulation"> micro encapsulation</a>, <a href="https://publications.waset.org/abstracts/search?q=supercritical%20carbon%20dioxide" title=" supercritical carbon dioxide"> supercritical carbon dioxide</a>, <a href="https://publications.waset.org/abstracts/search?q=non-toxic%20process" title=" non-toxic process "> non-toxic process </a> </p> <a href="https://publications.waset.org/abstracts/22475/synthesis-of-liposomal-vesicles-by-a-novel-supercritical-fluid-process" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/22475.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">431</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">47</span> Preparation and Physicochemical Characterization of Non-ionic Surfactant Vesicles Containing Itraconazole </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Ataei">S. Ataei</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Sarrafzadeh%20Javadi"> F. Sarrafzadeh Javadi</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Gilani"> K. Gilani</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20Moazeni"> E. Moazeni</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Drug delivery systems using colloidal particulate carriers such as niosomes or liposomes have distinct advantages over conventional dosage forms because the particles can act as drug-containing reservoirs. These carriers play an increasingly important role in drug delivery. Niosomes are vesicular delivery systems which result from the self-assembly of hydrated surfactant. Niosomes are now widely studied as an attractive to liposomes because they alleviate the disadvantages associated with liposomes, such as chemical instability, variable purity of phospholipids and high cost. The encapsulation of drugs in niosomes can decrease drug toxicity, increase the stability of drug and increase the penetrability of drug in the location of application, and may reduce the dose and systemic side effect. Nowadays, Niosomes are used by the pharmaceutical industry in manufacturing skin medications, eye medication, in cosmetic formulas and these vesicular systems can be used to deliver aspiratory drugs. One way of improving dispersion in the water phase and solubility of the hydrophobic drug is to formulate in into niosomes. Itraconazole (ITZ) was chosen as a model hydrophobic drug. This drug is water insoluble (solubility ~ 1 ng/ml at neutral pH), is a broad-spectrum triazole antifungal agent and is used to treat various fungal disease. This study aims to investigate the capability of forming itraconazole niosomes with Spans, Tweens, Brijs as non-ionic surfactants. To this end, various formulations of niosomes have been studied with regard to parameters such as the degree of containment and particle size. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=physicochemical" title="physicochemical">physicochemical</a>, <a href="https://publications.waset.org/abstracts/search?q=non-ionic%20surfactant%20vesicles" title=" non-ionic surfactant vesicles"> non-ionic surfactant vesicles</a>, <a href="https://publications.waset.org/abstracts/search?q=itraconazole" title=" itraconazole"> itraconazole</a> </p> <a href="https://publications.waset.org/abstracts/18011/preparation-and-physicochemical-characterization-of-non-ionic-surfactant-vesicles-containing-itraconazole" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18011.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">462</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">46</span> Liposome Sterile Filtration Fouling: The Impact of Transmembrane Pressure on Performance</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hercules%20Argyropoulos">Hercules Argyropoulos</a>, <a href="https://publications.waset.org/abstracts/search?q=Thomas%20F.%20Johnson"> Thomas F. Johnson</a>, <a href="https://publications.waset.org/abstracts/search?q=Nigel%20B%20Jackson"> Nigel B Jackson</a>, <a href="https://publications.waset.org/abstracts/search?q=Kalliopi%20Zourna"> Kalliopi Zourna</a>, <a href="https://publications.waset.org/abstracts/search?q=Daniel%20G.%20Bracewell"> Daniel G. Bracewell</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lipid encapsulation has become essential in drug delivery, notably for mRNA vaccines during the COVID-19 pandemic. However, their sterile filtration poses challenges due to the risk of deformation, filter fouling and product loss from adsorption onto the membrane. Choosing the right filtration membrane is crucial to maintain sterility and integrity while minimizing product loss. The objective of this study is to develop a rigorous analytical framework utilizing confocal microscopy and filtration blocking models to elucidate the fouling mechanisms of liposomes as a model system for this class of delivery vehicle during sterile filtration, particularly in response to variations in transmembrane pressure (TMP) during the filtration process. Experiments were conducted using fluorescent Lipoid S100 PC liposomes formulated by micro fluidization and characterized by Multi-Angle Dynamic Light Scattering. Dual-layer PES/PES and PES/PVDF membranes with 0.2 μm pores were used for filtration under constant pressure, cycling from 30 psi to 5 psi and back to 30 psi, with 5, 6, and 5-minute intervals. Cross-sectional membrane samples were prepared by microtome slicing and analyzed with confocal microscopy. Liposome characterization revealed a particle size range of 100-140 nm and an average concentration of 2.93x10¹¹ particles/mL. Goodness-of-fit analysis of flux decline data at varying TMPs identified the intermediate blocking model as most accurate at 30 psi and the cake filtration model at 5 psi. Membrane resistance analysis showed atypical behavior compared to therapeutic proteins, with resistance remaining below 1.38×10¹¹ m⁻¹ at 30 psi, increasing over fourfold at 5 psi, and then decreasing to 1-1.3-fold when pressure was returned to 30 psi. This suggests that increased flow/shear deforms liposomes enabling them to more effectively navigate membrane pores. Confocal microscopy indicated that liposome fouling mainly occurred in the upper parts of the dual-layer membrane. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=sterile%20filtration" title="sterile filtration">sterile filtration</a>, <a href="https://publications.waset.org/abstracts/search?q=membrane%20resistance" title=" membrane resistance"> membrane resistance</a>, <a href="https://publications.waset.org/abstracts/search?q=microfluidization" title=" microfluidization"> microfluidization</a>, <a href="https://publications.waset.org/abstracts/search?q=confocal%20microscopy" title=" confocal microscopy"> confocal microscopy</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=filtration%20blocking%20models" title=" filtration blocking models"> filtration blocking models</a> </p> <a href="https://publications.waset.org/abstracts/193171/liposome-sterile-filtration-fouling-the-impact-of-transmembrane-pressure-on-performance" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193171.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">19</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">45</span> Liposomal Antihelmintics in Parasitology</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nina%20Ivanova">Nina Ivanova</a> </p> <p class="card-text"><strong>Abstract:</strong></p> More than one third of the population and animals are infected with parasitic helminths. It is especially difficult to cure the larval forms of parasites. The larvae of Hymenolepis nana invade the villi of the intestinal mucosa. Toxocara larvae can live in the liver, heart, lungs, brain, eyes, and pancreas. Commercial antiparasitic drugs cannot guarantee a 100% cure after a single course of treatment, because parasite larvae invade the villi of the intestinal mucosa and the anthelmintics do not reach and kill cestode larvae. The aim of this work was to conduct a study of liposomal antihelminthics on the laboratory animals under the certification received from the Committee on Bioethics and Deontology. It has been checked: 1) anthelmintic activity of the liposomal form of fenasal in experimental hymenolepidosis of white mice (larval stage - Hymenolepis nana). 2) anthelmintic activity of the liposomal form of albendazole in experimental toxocariasis of white mice (in the lungs at the stage of larval migration). Since some helminths cause hemolysis of erythrocytes as we used a mixture of polar lipids developed by us with antihemolytic activity to obtain liposomes Fenasal and albendazole were included in the liposome membrane in the ratio of anthelmintic: lipids 1:10. . The average size of liposomes was 180 nm, and the concentration of lipids in liposomes was 1%. The researches were carried out on white male mice who were infected with Hymenolepis Nana invasional eggs in a peroral way with a doze of 100 eggs per animal. On the 5th day after infection, a liposomal fenasal and commercial fenasal were administered orally for comparison. The animals were observed for 15 days. Before the introduction of liposomes and on the 3rd, 5th, 15th day after the administration of the drug, studies were carried out on the presence of helminths in the organs of animals. The liposomal fenasal, when administered orally, had an anthelmintic effect on Hymenolepis Nana cysticercoids at a dose of 25 mg/kg. The percentage of efficiency was 90.06, 91.36 96.85% on days 3, 5, 15, respectively. For comparison, the commercial activity was at a dose of 200 mg/ml, which is 8 times higher than the dose of liposomal fenasal. To evaluate the anthelmintic effect of the liposomal form of albendazole in experimental toxocariasis of white mice (toxascaris in the lungs at the stage of larval migration), studies were also carried out on white mice. The animals were infected with invasive eggs of Toxocara canis, orally, at a dose of 100 eggs per animal. On the 5th day after infection, the liposomal albendazole was administered orally. The efficacy of the study dosage form was determined by counting Larva mirgans larvae in the lungs. The results obtained showed that the liposomal albendazole had the greatest anthelmintic effect on Toxocara larvae at a dose of 2.0 mg/kg, which was 3.75 times less than the therapeutic one. At the same time, the percentage of efficiency was 93.75% on the 3rd day, and 98.66% on the 5th day. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hymenolepis" title="hymenolepis">hymenolepis</a>, <a href="https://publications.waset.org/abstracts/search?q=Toxocara" title=" Toxocara"> Toxocara</a>, <a href="https://publications.waset.org/abstracts/search?q=larvae" title=" larvae"> larvae</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a> </p> <a href="https://publications.waset.org/abstracts/150739/liposomal-antihelmintics-in-parasitology" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/150739.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">113</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">44</span> Development of Drug Delivery Systems for Endoplasmic Reticulum Amino Peptidases Modulators Using Electrospinning</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Filipa%20Vasconcelos">Filipa Vasconcelos</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The administration of endoplasmic reticulum amino peptidases (ERAP1 or ERAP2) inhibitors can be used for therapeutic approaches against cancer and auto-immune diseases. However, one of the main shortcomings of drug delivery systems (DDS) is associated with the drug off-target distribution, which can lead to an increase in its side effects on the patient’s body. To overcome such limitations, the encapsulation of four representative compounds of ERAP inhibitors into Polycaprolactone (PCL), Polyvinyl-alcohol (PVA), crosslinked PVA, and PVA with nanoparticles (liposomes) electrospun fibrous meshes is proposed as a safe and controlled drug release system. The use of electrospun fibrous meshes as a DDS allows efficient solvent evaporation giving limited time to the encapsulated drug to recrystallize, continuous delivery of the drug while the fibers degrade, prevention of initial burst release (sustained release), tunable dosages, and the encapsulation of other agents. This is possible due to the fibers' small diameters and resemblance to the extracellular matrix (confirmed by scanning electron microscopy results), high specific surface area, and good mechanical strength/stability. Furthermore, release studies conducted on PCL, PVA, crosslinked PVA, and PVA with nanoparticles (liposomes) electrospun fibrous meshes with each of the ERAP compounds encapsulated demonstrated that they were capable of releasing >60%, 50%, 40%, and 45% of the total ERAP concentration, respectively. Fibrous meshes with ERAP_E compound encapsulated achieved higher released concentrations (75.65%, 62.41%, 56.05%, and 65.39%, respectively). Toxicity studies of fibrous meshes with encapsulated compounds are currently being accessed in vitro, as well as pharmacokinetics and dynamics studies. The last step includes the implantation of the drug-loaded fibrous meshes in vivo. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title="drug delivery">drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=electrospinning" title=" electrospinning"> electrospinning</a>, <a href="https://publications.waset.org/abstracts/search?q=ERAP%20inhibitors" title=" ERAP inhibitors"> ERAP inhibitors</a>, <a href="https://publications.waset.org/abstracts/search?q=liposomes" title=" liposomes"> liposomes</a> </p> <a href="https://publications.waset.org/abstracts/158961/development-of-drug-delivery-systems-for-endoplasmic-reticulum-amino-peptidases-modulators-using-electrospinning" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/158961.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">105</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">43</span> Nanoparticles-Protein Hybrid-Based Magnetic Liposome </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Amlan%20Kumar%20Das">Amlan Kumar Das</a>, <a href="https://publications.waset.org/abstracts/search?q=Avinash%20Marwal"> Avinash Marwal</a>, <a href="https://publications.waset.org/abstracts/search?q=Vikram%20Pareek"> Vikram Pareek</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Liposome plays an important role in medical and pharmaceutical science as e.g. nano scale drug carriers. Liposomes are vesicles of varying size consisting of a spherical lipid bilayer and an aqueous inner compartment. Magnet-driven liposome used for the targeted delivery of drugs to organs and tissues1. These liposome preparations contain encapsulated drug components and finely dispersed magnetic particles. Liposomes are vesicles of varying size consisting of a spherical lipid bilayer and an aqueous inner compartment that are generated in vitro. These are useful in terms of biocompatibility, biodegradability, and low toxicity, and can control biodistribution by changing the size, lipid composition, and physical characteristics2. Furthermore, liposomes can entrap both hydrophobic and hydrophilic drugs and are able to continuously release the entrapped substrate, thus being useful drug carriers. Magnetic liposomes (MLs) are phospholipid vesicles that encapsulate magneticor paramagnetic nanoparticles. They are applied as contrast agents for magnetic resonance imaging (MRI)3. The biological synthesis of nanoparticles using plant extracts plays an important role in the field of nanotechnology4. Green-synthesized magnetite nanoparticles-protein hybrid has been produced by treating Iron (III)/Iron(II) chloride with the leaf extract of Dhatura Inoxia. The phytochemicals present in the leaf extracts act as a reducing as well stabilizing agents preventing agglomeration, which include flavonoids, phenolic compounds, cardiac glycosides, proteins and sugars. The magnetite nanoparticles-protein hybrid has been trapped inside the aqueous core of the liposome prepared by reversed phase evaporation (REV) method using oleic and linoleic acid which has been shown to be driven under magnetic field confirming the formation magnetic liposome (ML). Chemical characterization of stealth magnetic liposome has been performed by breaking the liposome and release of magnetic nanoparticles. The presence iron has been confirmed by colour complex formation with KSCN and UV-Vis study using spectrophotometer Cary 60, Agilent. This magnet driven liposome using nanoparticles-protein hybrid can be a smart vesicles for the targeted drug delivery. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticles-protein%20hybrid" title="nanoparticles-protein hybrid">nanoparticles-protein hybrid</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20liposome" title=" magnetic liposome"> magnetic liposome</a>, <a href="https://publications.waset.org/abstracts/search?q=medical" title=" medical"> medical</a>, <a href="https://publications.waset.org/abstracts/search?q=pharmaceutical%20science" title=" pharmaceutical science"> pharmaceutical science</a> </p> <a href="https://publications.waset.org/abstracts/15000/nanoparticles-protein-hybrid-based-magnetic-liposome" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/15000.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">248</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=PEGylated%20liposomes&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=PEGylated%20liposomes&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=PEGylated%20liposomes&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>